scholarly journals Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology

2019 ◽  
Vol 2019 ◽  
pp. 1-15 ◽  
Author(s):  
Johnatas D. Silva ◽  
Ligia L. de Castro ◽  
Cassia L. Braga ◽  
Gisele P. Oliveira ◽  
Stefano A. Trivelin ◽  
...  

Although mesenchymal stromal cells (MSCs) have demonstrated beneficial effects on experimental acute respiratory distress syndrome (ARDS), preconditioning may be required to potentiate their therapeutic effects. Additionally, administration of cell-free products, such as extracellular vesicles (EVs) obtained from MSC-conditioned media, might be as effective as MSCs. In this study, we comparatively evaluated the effects of MSCs, preconditioned or not with serum collected from mice with pulmonary or extrapulmonary ARDS (ARDSp and ARDSexp, respectively), and the EVs derived from these cells on lung inflammation and remodeling in ARDSp and ARDSexp mice. Administration of MSCs (preconditioned or not), but not their EVs, reduced static lung elastance, interstitial edema, and collagen fiber content in both ARDSp and ARDSexp. Although MSCs and EVs reduced alveolar collapse and neutrophil cell counts in lung tissue, therapeutic responses were superior in mice receiving MSCs, regardless of preconditioning. Despite higher total cell, macrophage, and neutrophil counts in bronchoalveolar lavage fluid in ARDSp than ARDSexp, MSCs and EVs (preconditioned or not) led to a similar decrease. In ARDSp, both MSCs and EVs, regardless of preconditioning, reduced levels of tumor necrosis factor- (TNF-) α, interleukin-6, keratinocyte chemoattractant (KC), vascular endothelial growth factor (VEGF), and transforming growth factor- (TGF-) β in lung homogenates. In ARDSexp, TNF-α, interleukin-6, and KC levels were reduced by MSCs and EVs, preconditioned or not; only MSCs reduced VEGF levels, while TGF-β levels were similarly increased in ARDSexp treated either with saline, MSCs, or EVs, regardless of preconditioning. In conclusion, MSCs yielded greater overall improvement in ARDS in comparison to EVs derived from the same number of cells and regardless of the preconditioning status. However, the effects of MSCs and EVs differed according to ARDS etiology.

2015 ◽  
Vol 4 (10) ◽  
pp. 1199-1213 ◽  
Author(s):  
Oscar E. Simonson ◽  
Dimitrios Mougiakakos ◽  
Nina Heldring ◽  
Giulio Bassi ◽  
Henrik J. Johansson ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Sara Rolandsson Enes ◽  
Anna D. Krasnodembskaya ◽  
Karen English ◽  
Claudia C. Dos Santos ◽  
Daniel J. Weiss

Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.


2015 ◽  
Vol 5 (6) ◽  
pp. 845-845 ◽  
Author(s):  
Oscar E. Simonson ◽  
Dimitrios Mougiakakos ◽  
Nina Heldring ◽  
Giulio Bassi ◽  
Henrik J. Johansson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document